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The human epithelial proteinase inhibitor SKALP/ela­
fin and the porcine sodium-potassium ATPase inhibitor 
SPAI-2 are two highly homologous proteins that share 
an NHZ-terminal transglutaminase substrate domain 
and a COOH-terminal whey acidic protein (WAP) do­
main. Here we describe the bovine and simian orthologs 
of SKALP/elafin as well as two new bovine family mem­
bers that are designated Trappin-4 and Trappin-5 on the 
basis of a new nomenclature that we propose (Trappin = 
TRansglutaminase substrate and WAP motif-containing 
ProteIN). Sequence analysis of Trappin-4 and Trappin-5 
revealed a domain structure that is very similar to 
SPAI-2 (Trappin-1) and SKALP/elafin (Trappin-2). The 
transglutaminase substrate motifs are conserved al­
though the number of repeats varies among species and 
among family members. The sequence of Trappin-4 and 
Trappin-5 diverges from Trappin-1 and Trappin-2 at the 
putative reactive site in the WAP domain. The bovine 
ortholog of Trappin-2 is expressed in tongue and snout 
epidermis; Trappin-4 is expressed in trachea, ileum, and 
tongue; and Trappin-5 is expressed at low levels in  tra­
chea, as determined by RNase protection and Northern 
blot analysis. Based on the analysis of 67 transglutami­
nase substrate repeats as present in all known Trappin 
gene family members from four different mammalian 
species a consensus sequence could be established: Gly- 
Gln-Asp-Pro-Val-Lys (GQDPVK). Using biotiuylated  
hexapeptide probes we found that the GQDPVK se­
quence is a very efficient transglutaminase substrate 
both for guinea pig* liver transglutaminase and for epi­
dermal transglutaminase, and it acts as acyl donor as 
well as acceptor. We propose that the Trappin protein 
family forms a new group of enzyme inhibitors with 
various specificities of the WAP domain, which share 
transglutaminase substrate motifs that can act as an 
anchoring sequence.
Sldn-derived antileukoproteinase (SKALP)1 (1) and sodium- 
potassium ATPase inhibitor-2 (SPAI-2) (2) are two molecules 
that share an NH2-terminal domain that functions as a trans­
* The costs of publication of this article were defrayed in part by the 
payment of page charges. This article m ust therefore be hereby marked 
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to 
indicate this fact.
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1 The abbreviations used are: SKALP, skin-derived antileukoprotein­
ase; SPAI-2, sodium-potassium ATPase inhibitor-2; TGase, transglu­
taminase; WAP, whey acidic protein; SLPI, secretory leukocyte protein­
ase inhibitor; PCR, polymerase chain reaction; LI, lamellar ichthyosis; 
PAGE, polyacrylamide gel electrophoresis.
glutaminase (TGase) substrate, and a COOH-terminal whey 
acidic protein (WAP) domain that harbors an inhibitory activ­
ity toward at least two distinct enzymes* Porcine SPAI-2 was 
the first of these molecules to be described and is expressed 
mainly in the intestine (3). Human SKALP, otherwise known 
as elafin (4), or elastase-specific inhibitor (5), is a potent inhib­
itor of the leukocytic proteinases elastase and proteinase-3 (6 , 
7). We found that SKALP/elafin is expressed in several human 
stratifying squamous epithelia, except for epidermis where it is 
only expressed in the context of inflammation, such as psoriasis 
or wound healing (8-10), We mapped the genomic localization 
of human SKALP/elafin to chromosome 20q l2-13 (11). Inter­
estingly, this region contains various other genes involved in 
TGase-mediated cross-linking processes such as the tissue 
TGase gene (12), epidermal TGase (13, 14), and the genes 
coding for semenogelin I and semenogelin II (15), which are 
also epithelial TGase substrates. SKALP/elafin is distinct from 
SPAI-2 on the basis of its inhibitory activity, the amino acid 
sequence of the putative active site, and the epithelial expres­
sion pattern. The cDNAs and genes for porcine SPAI-2 (2, 3), 
porcine SKALP/elafin (16), human SKALP/elafin. (7, 17), and a 
new porcine family member (16) that is more similar to SPAI-2 
than to SKALP/elafin, have been cloned and revealed a high 
degree of conservation in the gene structure and the intronic 
sequences but a strong sequence divergence in the second exon.
The SKALP/SPAI-2 gene family members are composed of 
two evolutionary building blocks that are found in other pro­
teins as well (Fig. 1), The COOH-terminal WAP domain is 
homologous to the second domain of secretory leukocyte pro­
teinase inhibitor (SLPI), which inhibits elastase and cathepsin 
G (18). The NH2-terminal domain, containing the TGase sub­
strate motifs, is homologous to the guinea pig seminal vesicle 
protein-1 (19) and the human semenogelins (15). We showed 
that the NHa-terminal TGase substrate domain, for which the 
name “cementoin” was coined by others (20), is actually used in 
vivo and in vitro for cross-linking to stratum corneum proteins. 
Recently, it was shown by direct sequencing of cross-linked 
peptides from human foreskin epidermis that SKALP/elafin is 
cross-linked in vivo to loricrin and cytokeratin-1 (21), which are 
structural proteins of the terminally differentiating keratino- 
cyte. The cross-linked SKALP/elafin is proteolytically pro­
cessed further by unidentified proteinases to yield low molec­
ular weight COOH-terminal fragments containing the 
antiproteinase activity, starting at amino acid positions 149, 
151 and 156 (numbering according to Fig, 2), as shown by 
NH2-terminal sequencing of purified SKALP/elafin from epi­
dermal scale extracts (7, 10). We have found th a t the COOH- 
terminal part of SKALP/elafin is cleared via the plasma and 
can be recovered from the urine (22, 23). This mechanism 
provides the epidermis with an anchored proteinase inhibitor,
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Fig. 1. Schem atic  re p re se n ta t io n  of p ro te in s  w ith  a  WAP do­
m ain  andVor TGase s u b s tra te  motifs. The boxed S  indicates the 
signal peptide. Panel A , protein structure of SPAI-2 and SKALP/elafin 
that share an NHa-terminal TGase (TG) substrate domain and a 
COOH-terminal WAP domain. Panel B , protein structure of SLPI, 
which consists of two WAP domains. The COOH-terminal WAP domain 
of SLPI harbors proteinase inhibitory activity and is homologous to 
SKALP/elafin. Panel C, schematic structure of the seminal vesicle pro­
tein-1 and the human semenogelins. These proteins contain a domain 
that consists of TGase substrate motifs.
which could protect the structural proteins of the stratum 
comeurn against unwanted proteolysis; in addition it gener­
ates, after cleavage, a gradient of low molecular weight inhib­
itors from the epidermis to the dermis, thereby possibly inter­
fering with polymorphonuclear leukocyte chemotaxis and 
polymorphonuclear leukocyte-induced degradation of extracel­
lular matrix proteins such as elastin and basal membrane 
components.
To study the evolutionary divergence of SKALP/elafin in 
various species and to identify potential new members of this 
gene family we performed reverse transcription-polymerase 
chain reaction (PCR) on mRNA of epithelial tissues from var­
ious mammals, using degenerate primers that encompass the 
TGase substrate domain and the WAP domain. In this way we 
identified the putative simian and bovine orthologs of SKALP/ 
elafin, and we have identified two new family members from 
bovine tissue. On the basis of the family members thus far 
identified we propose a new unifying nomenclature. Prom all 
known SKALP/elafin gene family members in various species 
we derived a consensus hexapeptide sequence for the TGase 
substrate motif. Using synthetic peptides we show that this 
hexapeptide motif is an extremely efficient substrate for vari­
ous TGases.
4
EXPERIMENTAL PROCEDURES
Tissues—Bovine and simian (rhesus monkey) tissues were obtained 
from the central animal laboratory, University of Nijmegen, The Neth­
erlands. Spontaneously shed scales from psoriatic, eczema, and lamel­
lar ichthyosis (LI) patients were collected and stored at -2 0  *C. The LI 
patient was homozygous for a splice site mutation in intron 5 of the 
TGase 1 gene as determined by single strand conformation polymor­
phism analysis and sequence analysis. This mutation causes a defi­
ciency for TGase type 1 as recently described (24).
RNA Isolation and cDNA Synthesis — Total RNA from bovine tongue 
and rhesus monkey skin were extracted with RNAzol B as suggested by 
the supplier (Cinna/Biotex). First strand cDNA was generated from 
total RNA with Moloney murine leukemia virus range H" reverse 
transcriptase (Expand Reverse Transcriptase, Boehringer Mannheim) 
under conditions as suggested by the supplier, using excess oligo(dT) 
primers. The reverse transcriptase reaction products were used for PCR 
amplification to obtain the partial cDNA of bovine and simian orthologs 
of SKALP/elafin.
PCR; Cloning and Sequencing of PCR Products — Based on conserved 
amino acid stretches within SKALP/elafin and porcine SPAI-2 we de­
signed two oligonucleotide forward primers (positions are shown in Fig. 
2): primer SKAl, 5'-AGGGCCAGCAGCTTCTTGATC-3'; and primer 
SKA2, 5 '-CAAGA(G/T)CCAGTCAA(A/G)GGT-3'. As reverse oligonu­
cleotide primers we used primer SKA3, 5'-CAGCACTTCTTGA(C/T)(C/ 
T)CCTGG-3' and the oligo(dT) primer (Fig. 2). PCRs were carried out 
using a DNA thermal cycler (PTC-200, Biozym) in  25-jnl mixtures. The 
following buffer conditions were used; 10 mM Tris-HCl, pH 8.8, 1.5 mM 
magnesium chloride, 50 mM potassium chloride, 0.1% Triton X-100, all 
four dNTPs (each at 200 /xM), 2 units of PrimeZyme DNA polymerase 
(Biometra), and 20 pmol of each primer. After an initial incubation of 6 
min at 94 °C amplification was conducted for 35 cycles as follows: 1 min 
at 94 °C, 1 min at annealing temperature, and 2 min at 72 QC. An 
additional 10 min at 72 °C was used for the last cycle. Annealing
temperatures were 57 °C when using primers SKAl and SKA3, 55 °C 
for primers SKA2 and SKA3, 51 °C for primer SKÀ2 and the oligo(dT) 
primer. The PCR products were purified from agarose gel and cloned 
into the pGEM-T vector (Promega) according to the protocol provided by 
the manufacturer. Blunted PCR fragments were cloned into a Smal- 
digested pBluescript KS(+) vector (Stratagene). Both strands were 
sequenced using the dideoxy chain termination procedure (25).
DNA sequence gel readings were recorded, edited, and assembled 
using the GCG package (26) provided by the Dutch CAOS/CAMM 
center. Deduced protein sequences and alignments were analyzed with 
the same software.
RNase Protection Assay—Total RNA from different bovine tissues 
was extracted with RNAzol B as suggested by the supplier. The follow­
ing bovine tissues were studied; tongue, kidney, liver, trachea, lung, 
ileum, epidermal skin from snout, brain, and esophagus. The 360-base 
pair blunt fragment encoding the  possible bovine ortholog of human 
SKALP/elafin (Trappin-2) was cloned into the Sm a I site of the pBlue­
script KS(+) vector, which contains the T3 promoter for transcription of 
antisense RNA. In vitro transcription was performed using a  transcrip­
tion kit (Boehringer Mannheim) in  the presence of [a-a2P]UTP (Amer- 
sham). Antisense RNA probe was transcribed from the Xbal-linearized 
SKALP/elafin (bovine Trappin-2) template. DNA template was de­
graded with RNase-free DNase I, and th e  labeled RNA probe was 
purified using Chroma spin+TE-100 columns (CLONTECH), acidic 
phenol/chloroform extraction, and ethanol precipitation. Using the 
RNase protection kit (Boehringer Mannheim), the radioactively labeled 
probe (1 X 105 cpm) was hybridized to 10 fxg of total RNA from different 
bovine tissues or to 10 jug of total RNA from human psoriatic skin 
biopsies as a negative control. Samples were denatured for 10 min at 
80 °C followed by an overnight incubation a t 55 °C. Partial RNA’RNA 
hybrids were treated with DNase-free RNase A and RNase 'I \  according 
to the manufacturer’s instructions. The protected RNA fragments were 
subjected to electrophoresis on a 6% denaturing polyacrylamide gel 
containing 7 M urea and were sized using the  sequencing reaction of the 
PCR product encoding bovine Trappin-2. Autoradiography was per­
formed on Biomax-MR films (Kodak) a t  -8 0  °C with intensifying 
screens. Processing of the autoradiographs was performed using the 
Imagemaster™ data image system (Pharmacia Biotech Inc.).
Northern Blot Analysis — For Northern blot analysis, 10 /ig of total 
RNA from different bovine tissues was electrophoretic ally separated in 
a 1% agarose gel (dissolved in 10 mM sodium phosphate buffer, pH 7.0), 
as described before (27). The gel was blotted by capillary transfer onto 
positively charged nylon membrane (Boehringer Mannheim) using 10 X 
SSC (1.5 M sodium chloride, 0.15 M sodium citrate). After transfer, RNA 
was fixed to the membrane by ultraviolet irradiation (312 nm, 0.2 
J/cm2), The membrane was incubated with ethidium bromide (1 /ig/ml) 
for 15 min prior to photography. Hybridization was performed in 250 
mM phosphate buffer a t 60 °C according to Church and Gilbert (28), 
using 32P-labeled random primed probes encoding bovine Trappin-4 
and -5 obtained by reverse transcription-PCR. The blot was washed 
twice for 15 min at 60 °C using 125 mM phosphate buffer. Autoradiog­
raphy was performed on Biomax-MR films a t -8 0  °C with intensifying 
screens. Processing of the autoradiographs was performed using the 
Imagemaster™ data image system.
Biotinylated Peptides—Six hexapeptides with an NH2-terminal bio­
tin followed by a CG-spacer were synthesized: GQDPVK, GQDPVR, 
GNDPVK, GNDPVR, KVPDQG and GKDPVQ (Eurosequence Inc., 
Groningen, The Netherlands). 250 \u,g of a hexapeptide (TVQQEL) and 
a heptapeptide (PGGQQIV), two known acyl donor probes in  the TGase 
assay (29), were biotinylated with 500 fig of NHS-LC-biotin (Pierce) for
2 h at 37 °C in 300 /ul of 0.1 M N a2C 0 3, pH 8.0. The reaction was stopped 
by the addition of 20 fxl of 1 M Tris, pH 8.0 (30).
Cross-linking of the Biotinylated Peptides to Stratum Corneum Pro­
teins by Endogenous TGase — Epidermal scales from a psoriatic patient 
(200 mg) were homogenized in 4 m l of buffer containing 50 mM Tris- 
HCl, pH 7.8, 100 mM sodium chloride, and 1 mM phenylmethylsulfonyl 
fluoride (Sigma), and centrifuged for 30 min at 25,000 X g. The same 
protocol was used for scales from patients with eczema and LI. The 
supernatants were stored at —20 °C until further use. For cross-linking 
experiments 10 /jl of scale extract was used with 5 jul (100 jig/ml) of 
biotinylated peptide. The following buffer conditions were used: 50 mM 
Tris-HCl, pH 7.8, 100 mM sodium chloride, and calcium chloride at a 
concentration of 2 mM, in a final reaction volume of 50 \id. In some 
experiments 2 jul (0.0313 unit/ml) of guinea pig liver TGase (Sigma) was 
added. After 60 min at 37 °C, the reaction was stopped by the addition 
of 5 fx1 of 100 mM EDTA, pH 7.8. Reaction mixtures containing 10 mM 
ED TA, pH 7.8, and heat-inactivated scale extracts were used as con­
trols. The reaction mixtures were blotted directly onto polyvinylidene
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F ig. 2. A lignm ent of am ino  a c id  seq u en ces  of m em b ers  f ro m  th e  T ra p p in  p ro te in  fam ily. The amino acid sequences (single letter code) 
of the novel bovine Trappins (bTRAPPIN-4 and -5) and the bovine and simian orthologs of SKALP/elafin (bTRAPPIN-2 and sTRAPPIN-2) are 
deduced from the partial cDNA sequences obtained, by reverse transcription-PCR (primer sequences are excluded). Comparisons with human 
SKALP/elafin (hTrappin-2), porcine SKALP/elafin (pTrappin-2), the porcine sodium-potassium ATPase inhibitor SPAI-2 (pTrappin-l), and a new 
porcine family member (pTrappin-3) are shown. The italicized amino acid residues (from position 176 to 182) correspond to the known active site 
region of SLPI which is a protein th a t  consists of two WAP motifs (18, 57), The binding site of SKALP/elafin with elastase is found at the amino 
acid sequence Leu17ö(P5)-Leulö2(P2'), which contains the scissile peptide bond AlaI8fl-Met181 (35), which is marked by a vertical arrow (4 ). The 
hydrophobic signal sequences of hTrappin-2 (7) and pTrappin-l (2) are indicated in bold. A phase-1 intron (§> <g) (between the first and second 
nucleotides of the codon for the amino acid a t position 42 separates the  exon coding for the signal sequence from the TGase substrate domain. The 
hexapeptide repeats in the Trappins are grouped in the second and third blocks of the alignment. As pointed out by Tamechika et al. (16), expansion 
and contraction of the number of hexapep tides in this gene family occur readily, presumably as a result of gene conversions and DNA polymerase 
slippage. Some sequence similarities suggestive of conversions among the three porcine Trappin genes are underlined. E ight conserved cysteine 
residues involved in the formation of the WAP motif or four-disulfide core structure of the Trappin gene family are indicated (v). Amino acid 
residues with 100% conservation are indicated with asterisks (*). The positions of the oligonucleotide forward primers (ska ï and ska2) and reverse 
primers (ska3 and oligo-dT) used in  the PCR are indicated.
difluoride membranes (Millipore) by a slot-blot manifold or were sub­
jected to SDS-PAGE (12% Ready gel, Bio-Rad) and blotted onto polyvi- 
nylidene difluoride membrane. Biotinylated proteins were detected 
with the Western Light k it (Tropix) according to the manufacturer’s 
instructions. This assay uses avidin-conjugated alkaline phosphatase 
and chemiluminescence of a sensitive alkaline phosphatase substrate. 
Positive bands were recorded on X-Omat S i  films (Kodak) and were 
processed with a maximum scanning OD range of 1.5 and quantitated 
using the Imagemaster™ data image system.
Cross-linking of the Biotinylated Peptides to Purified Proteins by 
Exogenous TGase—Purified bovine crystallin proteins aB, /3-low, 7, and 
aA  were prepared as described previously (30, 31). Recombinant hum an 
SKALP/elafin, containing amino acids 151-213 (numbering according 
to Fig. 2) of the complete amino acid sequence of SKALP as described by 
Molhuizen et al. (7), was a kind gift of Dr, N, Russel, Zeneca, TJ. K. 
Bovine serum albumin was from Boehringer Mannheim. For cross- 
linking experiments 20 /il of protein (1 mg/ml) was used with 0.5 nmol
of biotinylated GQDPVK peptide and 2 (jl\  of guinea liver pig TGase 
(0.0313 units/ml) under reaction conditions as described in the previous 
paragraph,
SDS-PAGE and Western B lotting—TGase assay reaction mixtures 
were diluted with SDS-sample buffer (containing dithiothreitol) and 
boiled for 2 min. These protein samples were separated by SDS-PAGE 
on a 12% Tris-glycine gel (Ready gels, Bio-Rad) using Tris-glycine as 
electrophoresis buffer (32). The broad range prestained marker from 
Bio-Rad was used as molecular marker (myosin (208 kDa), ß-galacto- 
sidase (116 kDa), bovine serum albumin (79 kDa), ovalbumin (49 kDa), 
carbonic anhydrase (34 kDa), soybean trypsin inhibitor (28 kDa), ly- 
sozyme (28 kDa), and aprotinin (6,5 kDa)). Gels were electroblotted onto 
polyvinylidene difLuoride membranes, and protein staining was per­
formed with Amido Black according to standard  procedures.
Keratinocyte Secondary Culture—U nman  primary kératinocytes» 
cultured according to the Rheinwald-Green system (33), were seeded a t 
10s cells in keratinocyte growth medium in 60-mm culture dishes as
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Table I
Sequence comparison between the WAP domains as present in the various Trappin protein fam ily members
Upper right, identities in percentage; lower left, similarities In percentage. For comparison 32 amino acid residues were used (residues at 
positions 163 to 194 in Fig. 2).
hTrappin-2 sTrappin-2 pTrappin-2 bTrappin-2 bTrappin-4 bTrappin-5 pTrappin-l pTrappin-3
hTrappin-2 97 69 75
sTrappin-2 97 69 75
pTrappin-2 78 78 81
bTrappin-2 91 91 88
bTrappin-4 77 77 87 88
bTrappin-5 74 74 81 SI
pTrappin-l 63 63 69 69
pTrappin-3 66 66 72 75
described by van Ruissen et al. (34). Keratinocyte growth medium was 
composed of ICBM (Clonetics; 0.15 mM calcium) supplemented with 
ethanolamine (Sigma; 0.1 mM), phosphoethanolamine (Sigma; 0.1 mM), 
bovine pituitary extract (Clonetics; 0.4% v/v), epidermal growth factor 
(Sigma; 10 ng/ml), insulin (Sigma; 5 jug/ml), hydrocortisone (Collabora­
tive Research Inc.; 0.5 jug/ml), penicillin (Life Technologies, Inc.; 100 
units/ml), and streptomycin (Life Technologies, Inc.; 100 jug/ml). Kera­
tinocyte differentiation was induced by switching confluent keratino­
cyte cultures for 48 h to keratinocyte growth medium containing high 
(1.8 mM) calcium. Cell extracts were prepared in 200 jul of water by 
sonification on ice, followed by centrifugation for 10 min at 25,000 X g. 
The supernatants were stored at -2 0  °C until further use.
RESULTS AND DISCUSSION
Cloning and Sequence Analysis of Bovine and Simian 
SKALP fElafin Orthologs and Two New Bovine Members of the 
SKALP IElafin Gene Family; Suggestions for a New Nomencla­
ture—To isolate partial cDNAs of bovine and simian SKALP/ 
elafin orthologs, three oligonucleotide primers (Fig. 2) were 
designed based on conserved sequences within human SKALP/ 
elafin and porcine SPAI-2. Using total RNA derived from bo­
vine tongue and rhesus monkey skin, first strand cDNA was 
generated in a reverse transcriptase reaction and amplified by 
PCR with the designed primers. PCR products were cloned and 
sequenced. Four clones were identified as members of the 
SKALP/elafm gene family based on the presence of sequences 
encoding an NHz-terminal TGase substrate domain and a 
COOH-terminal WAP-domain. Computer-assisted comparison 
with published sequences of this gene family was performed to 
reveal the possible identity of the clones. Fig. 2 shows the 
alignment of the deduced amino acid sequences of the four 
clones with the currently known family members. Two se­
quences can be regarded as the simian and bovine orthologs of 
SKALP/elafin. Overall, simian SKALP/elafin is 93% identical 
to human SKALP/elafin, and bovine SKALP/elafm is 71% iden­
tical to porcine SKALP/elafin. Within a part of the WAP do­
main (amino acid residues at positions 163-194 in Fig. 2) these 
percentages are 97% and 81%, respectively (Table I). The se­
quences of the putative active sites (residues italicized in Fig. 
2) of both simian and bovine SKALP/elafin closely correspond 
to the known protease binding site of SKALP/elafin (35) and 
the pro tease binding site of SLPI (36) which also belongs to the 
WAP protein superfamily. The homology in the putative active 
site of both simian and bovine SKALP/elafm suggests that 
these molecules could be elastase inhibitors, although we have 
no data from functional studies to substantiate this contention. 
It was, however, shown recently that the porcine SKALP/elafin 
ortholog is indeed an inhibitor of at least porcine pancreatic 
elastase (16).
At present, the nomenclature of the proteins containing an 
NH2-terminal TGase substrate domain and a COOH-terminal 
WAP-domain is very confusing. Until now porcine SPAI-2 (2) 
and the proteinase inhibitor SKALP/elafin/elastase-specific in­
hibitor were described in the literature (1, 7, 17, 37). For the 
NH2-terminal TGase substrate domain a separate name, ce-
55 52 47 44
55 52 47 44
68 61 53 47
74 68 53 47
93 48 42
93 48 39
68 68 59
68 65 69
mentoin, was coined by Nara et aL (20). Here we propose to give 
these proteins the acronym Trappin (Trappin = TRansglu- 
taminase substrate and WAP motif-containing ProteIN) as a 
new nomenclature for this protein family. Since SPAI-2 and 
SKALP/elafin/elastase-specific inhibitor were the first mem­
bers to be described, these are designated Trappin-1 and Trap- 
pin-2, respectively. Trappin-3 is a new porcine member of this 
gene family which was called pWAP-3 by Tamechika et al. (16). 
The two other sequences from bovine tongue we identified (see 
Fig. 2) are new members of the SKALP/elafin gene family and 
are designated Trappin-4 and Trappin-5 on the basis of the new 
nomenclature that we proposed. Sequence analysis of these 
new members of the Trappin gene family revealed a domain 
structure that is very similar to porcine SPAI-2 (Trappin-1) and 
human SKALP/elafin/elastase-specific inhibitor (Trappin-2). 
The sequence of Trappin-4 and Trappin-5 diverges from 
SKALP/elafm and SLPI at the putative reactive site; however, 
the cysteine residues of the four-disulfide core structure ob­
tained from the partial cDNA sequence are conserved. The 
biological function of these new bovine Trappin gene family 
members is not known. The putative reactive site region in 
Trappin-4 and Trappin-5 is distinct from SLPI and SKALP/ 
elafin at the Met181 and Leu182 residues (numbering according 
to Fig. 2) and could possibly lead to dissimilar functions. Di­
versity in biological functions among SKALP/elafin, SLPI, and 
SPAI-2 could be the result of the differences in residues around 
the protease cleavage site within the WAP domain (see Fig. 2). 
(Amino acid residues of substrates numbered PI, P2, etc., are 
toward the NH2-terminal direction, and PI', P2 ', etc., are to­
ward the COOH-terminal direction from the scissile bond, as in 
the nomenclature of Schechter and Berger (38)). The preferable 
residues at P I' and P2 ' in a-lytic protease, which demonstrates 
an elastase-like primary specificity, are, respectively, methio­
nine and leucine (39). As the scissile peptide bond in SKALP/ 
elafin and SLPI is Ala180(Pl)-Met181(Pr), these proteins hold 
the preferable residues at Met181 (P1') and Leu182(P2 '), sug­
gesting a specificity like a-lytic protease (35). Although porcine 
SKALP/elafin varies from human SKALP/elafin and SLPI at 
the PI and P2' residue, this protein shows the ability to inhibit 
porcine pancreatic elastase (16), suggesting that the conserved 
Met181 residue is necessary for elastase specificity. An intact 
methionine is required for human SKALP/elafm to act as a 
high affinity inhibitor of leukocyte elastase (35). The putative 
reactive site in the new bovine Trappin gene family members 
Trappin-4 and Trappin-5 lacks this methionine residue, which 
makes it unlikely that these proteins are elastase inhibitors. 
Recently, Trappin-3 was described (16) which is 59% identical 
to Trappin-1 within a part of the WAP domain (amino acid 
residues 163-194 according to Fig. 2 ). Comparison of our new 
family members Trappin-4 and -5 with porcine Trappin-1 and 
Trappin-3 revealed less than 48% identity. Trappin-4 and -5 
share a 93% identity. On the basis of sequence identity in the 
active site, the Trappin family members can be divided in three
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Pig. 3. Tissue d is t r ib u t io n  of bo v ine  T ra p p in  fam ily  m em b ers  
by RNase P ro te c t io n  a n d  N o r th e rn  b lo t analysis . Panel A, analy­
sis of bovine Trappin-2 expression by RNase protection assay. Total 
RNA (10 fig) from different bovine tissues was incubated with a :i2P- 
labeled cRNA probe specific for the bovine Trappin-2. After digestion 
with RNase A and RNase the protected fragments were subjected to 
electrophoresis on a 6% denaturing polyacrylamide gel containing 7 m  
urea. Lanes 1-9 , respectively, represent the bovine tissues from kidney, 
liver, trachea, lung, ileum, epidermis from bovine snout, brain, esoph­
agus, and tongue. Lane 10 is human psoriatic skin as a negative control. 
Panel B , analysis of Trappin-4 expression by Northern blot analysis. 10 
fig of total RNA was loaded and electrophoretically separated. Hybrid­
ization was performed with a 32P-labeled bovine Trappin-4 probe. Panel
C, analysis of Trappin-5 by Northern blot analysis. Hybridization was 
performed with a 3aP-labeled bovine Trappin-5 probe.
subgroups: Trappin-1 and -3, Trappin-4 and -5, and Trappin-2 
(Table I),
Tissue Distribution o f Trappin Family Members—The. Trap­
pin gene family members exhibit distinct tissue distributions. 
Porcine Trappin-1 (SPAI-2) was previously found to be abun­
dantly expressed in the intestine, whereas porcine Trappin-3 is 
found in the intestine at relatively low levels (16). The mRNA 
for porcine Trappin-2 (SKALP/elafm) was mainly found in tra­
chea and large intestine. This is different from human Trap­
pin-2 which is expressed in several human stratifying squa­
mous epithelia (9), except for epidermis where it is only 
expressed in the context of inflammation, such as psoriasis and 
wound healing (8 , 10). The observed differences could be the 
result of different sensitivity of the detection methods or could 
represent real species differences. To define tissue distribution 
patterns of bovine Trappin-2, expression of the Trappin-2 
mRNA was studied by RNase protection analysis. Protected 
bands with the expected length (360 base pairs) were detected 
in the tongue and in the epidermis of snout (Fig. 3A). As a 
negative control we used RNA from psoriatic skin, which con­
tains human Trappin-2 mRNA. Because human Trappin-2 has 
several mismatches compared with the bovine ortholog it will 
be degraded by RNase and is hence not visible on the gel. The 
expression of Trappin-4 and -5 mRNA in various bovine tissues 
was studied by conventional Northern blot analysis. Trappin-4 
is abundantly expressed in trachea, and a faint signal was 
found in ileum and tongue (Fig. 35), whereas Trappin-5 was 
expressed at relatively low levels in trachea (Fig. 3C). Trap­
pin-4 an -5 are very similar at the DNA level (88% overall 
identity), and therefore it cannot be totally excluded that the 
signal of the Trappin-5 probe on the Northern blot is the result 
of cross-hybridization.
The high level of sequence divergence in the short amino acid 
stretch encoding the inhibitor domain of this gene family can be 
viewed as an example of accelerated evolution as described by 
Tamechika et al. (16). This is a process assumed to take place 
in genes after a duplication event (40) and has been interpreted 
as an effective mechanism to create new reactive site sequences 
with different substrate specificities. These amino acid changes 
are established by positive Darwinian selection as first re­
ported by Hill and co-workers (41, 42), who described this 
phenomenon in the serine proteinase inhibitor (serpin) family.
Since the Trappin family members are all expressed in tissues 
that are exposed continuously to microbial stimuli (oral cavity, 
trachea, intestine) it raises the possibility that some of them 
are directed against bacterial proteinases rather than exclu­
sively against self-proteases (as Trappin-2, which is directed 
against leukocyte elastase and proteinase-3). This contention is 
supported by the recent finding that the distant family member 
SLPI, which is homologous to Trappins in its COOH-terminal 
domain, possesses antiviral and antibacterial activity (43, 44). 
The high substitution rates in the reactive center region of the 
Trappins could conceivably provide the host with a defense 
system against pathogens and parasites and give them the 
capacity to deal with an increasing number of attacking 
proteinases.
The TGase substrate motifs in the NH2-terminal part of the 
Trappins are conserved, although the number of amino acid 
repeats varies among species and among the Trappin gene 
family members. Porcine and bovine Trappin-2 display 11 and
12 repeats, respectively, whereas six repeats were found in 
human and simian Trappin-2. The deduced amino acid se­
quences of the novel members derived from bovine tongue, 
Trappin-4 and Trappin-5, both contained five repeats. Com­
bined with 14 repeats found in the published porcine Trappin-1 
protein and eight repeats in the new porcine family member 
Trappin-3, the frequency of amino acids at each position was 
calculated by comparing the total of 67 repeats in the putative 
TGase substrate domains of the currently known Trappin pro­
tein family members from four different mammalian species 
(Table II). In this way a consensus hexapeptide sequence of 
GQDPVK could be deduced, in agreement with earlier studies
(2, 7).
Conservation o f a TGase Substrate M otif in Members o f  the 
Trappin Gene Family —■To characterize further the biochemical 
properties of the above mentioned TGase consensus substrate 
motif, the biotinylated hexapeptide GQDPVK was synthesized, 
and enzyme kinetic experiments were performed using a TGase 
assay (29) to determine optimal reaction conditions. The TGase 
cross-linking reaction is based on a Ca2 ‘ -dependent exchange 
of primary amines for ammonia at the y-carboxamide group of 
glutamine residues. Peptide-bound lysine residues or poly­
amines serve as the primary amines to form either e-(y-glu- 
tamyDlysine or (y-glutamyl)poly amine bonds between proteins 
(45), which are highly resistant to chemical and enzymatic 
degradation (46). As human epidermis is known to contain both 
TGase activity (47, 48) and various substrate proteins (e.g. 
involucrin, loricrin, small proline-rich proteins) (21), an extract 
of psoriatic scales was used to study the incorporation of the 
biotinylated hexapeptide. A time course incubation at 37 °C of 
the biotinylated hexapeptide with scale extract showed that the 
reaction rate as measured by chemiluminescence detection was 
linear up to 3 h (data not shown), For further experiments a 
reaction time of 60 min was used for practical convenience. The 
effect of the peptide concentration on the rate of cross-linking to 
epidermal proteins by endogenous TGase is shown in Fig. 4. An 
apparent Km of 0.46 ju,m was found.
The protective callus layer resulting from terminal differen­
tiation of the squamous epithelium is thought to be cross- 
linked by different TGase activities present in mammalian 
epidermis. These T Gas es are probably involved in the forma­
tion of the cornified cell envelope of terminally differentiating 
epidermis and of other stratified squamous epithelia. Three 
TGases are expressed in the epidermis, a ubiquitous tissue 
type TGase (TGC or TGase 2), a membrane-associated kerati­
nocyte TGase (TGK or TGase 1) present in cultured epidermal 
keratinocytes and in many epithelial and nonepithelial tissues, 
and the zymogen epidermal TGase (TGE or TGase 3) known to
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Table II
Consensus amino acid sequence o f the TGase substrate m otif in various Trappin fam ily members
The established hexapeptide is derived from the frequency of amino acids at each position by comparing 67 repeats in the putative TGase 
substrate domain within eight members of the Trappin family from four different species. Hexapeptide sequences th a t  contain fewer than three 
residues identical to GQDPVK are excluded from the frequency calculation.
Position 1 2 3 4 5 6
Amino acid (frequency, in %) G (78) Q (87) D (67) P  (75) V  (84) K (81)
A (7) G (3) G (10) L (6) D (12) E (9)
V (3) R(3) V (6) S(4) G (3) N (4)
E(3) K (3) E(6) Q (4) F (I) R(3)
T (3) E ( l ) L (6) V (4) V (3)
S (3) P ( l ) S(3) T (3)
D (1) H (1) N (1) K (1)
L (1) RC1)
Q
O
<u
P<
o
gp
a>
ÉS
peptide concentration (jaM)
Fig. 4, E ffect o f p ep tid e  co n cen tra tio n  on  the  r a te  of cross- 
l in k in g  to ep id erm al p ro te in s  by endogenous TGase. The bioti­
nylated GQDPVK hexapeptide was incubated with scale extract from a 
psoriatic patient for 60 min a t 37 °C. The reaction mixture was blotted 
directly onto polyvinylidene difluoride membrane, and the biotinylated 
proteins were detected by chemiluminescence that was recorded on 
x-ray film and quantified by image analysis. An apparent Km of 0.46 pM 
was found.
be expressed in differentiated epidermal cells and hair follicles, 
but not in cultured epidermal keratinocytes (49-53). Incuba­
tion of the biotinylated GQDPVK hexapeptide with psoriatic 
scale extract leads to its cross-linking to stratum corneum 
proteins by Ca2+-activated endogenous TGase (Fig. 5A, sample 
1). Human epidermis and probably also stratum corneum are 
known to harbor TGases 1 , 2 ,  and 3 ( 2 1 , 47, 48). From our data, 
however, it cannot be concluded which type is responsible for 
cross-linking the biotinylated GQDPVK hexapeptide to sub­
strate proteins. Since TGase 1 and 3 are not available in puri­
fied form we only tested guinea pig liver TGase (type 2 TGase), 
and this was found to cause incorporation of the biotinylated 
hexapeptide into stratum corneum proteins of a native scale 
extract (sample 2) or scale extract that had been heat-inacti­
vated to eliminate endogenous TGase activity (sample 3); so 
both the TGases present in scale extract and type 2 TGase 
catalyze the incorporation of biotinylated peptide into stratum 
corneum proteins. Specificity of the reaction was checked by 
the omission of guinea pig liver TGase (sample 4) or the addi­
tion of excess EDTA (not shown).
The biotinylated GQDPVK hexapeptide appeared to be an 
extremely efficient TGase substrate that acts both as an acyl 
donor and as an acyl acceptor probe (Fig. 55). Substitution of 
the acyl acceptor residue lysine (K) for arginine (R) (sample 2) 
or substitution of the acyl donor residue glutamine (Q) for 
asparagine (N) (sample 3) showed no influence on cross-linking 
to stratum corneum proteins. Substitution of both the lysine 
and the glutamine residue for, respectively, arginine and as­
paragine, totally abolished cross-linking of the biotinylated 
hexapeptide (sample 4). The efficiency of cross-linking is se­
quence dependent as a hexapeptide in the reverse order (KVP- 
DQG, sample 5) or the exchange of lysine and glutamine (GK- 
DPVQ, sample 6) virtually eliminated cross-linking to stratum
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F ig. 5. C hem ilum inescen t d e te c t io n  of slot-blotted b io tin y ­
la te d  p ro te in s  d e m o n s tra t in g  T G ase-m ed ia ted  cross-linking of 
b io tin y la ted  pep tides  to  s t r a tu m  c o rn e u m  p ro te in s  and  p u rif ied  
p ro te ins . Panel A: I ,  biotinylated GQDPVK hexapeptide incubated 
with psoriatic scale extract; 2, scale extract with exogenous type 2 
TGase; 3, heat-inactivated scale extract with exogenous type 2 TGase; 
4 , heat-inactivated scale extract without exogenous TGase. Panel B , 
scale extract from a psoriatic patient incubated with different biotiny­
lated peptides: GQDPVK (1), GQDPVR (2), GNDPVK (3), GNDPVR (4 \ 
KVPDQG (5), and GKDPVQ (6). Panel C, cross-linking of the biotiny­
lated GQDPVK hexapeptide to different acceptor proteins by type 2 
TGase: bovine serum albumin (2), recombinant COOH-terminal domain 
of SKALP/elafin (2 ), y-crystallin (3), aB -crystallin (4), aA-crystallin (5), 
and ß-low-crystallin (6). Panel D, cross-linking of different biotinylated 
peptides to stratum corneum proteins by endogenous TGases in a scale 
extract from a psoriatic patient: GQDPVK (1), TVQQEL (2), and PG- 
GQQTV (3), Panel D also shows cross-linking of these peptides to /3-low- 
crystallin by type 2 TGase (4—6). Panel E , cross-linking of the biotiny­
lated GQDPVK hexapeptide to stra tum  corneum proteins by 
endogenous TGase in scale extracts from three psoriatic patients (1-3)t 
in scale extract from a patient with LI (4)t and in scale extract from a 
patient with eczema (5).
corneum proteins. Whether these negative effects on substrate 
reactivity are the result of changes in structural conformation 
of the peptide or are a consequence of changing the chemical 
nature of the side chains surrounding the substrate lysine and 
glutamine is not clear. Grootjans et aL (29) showed that some 
residues directly preceding the substrate lysines have a nega­
tive effect on TGase activity. These residues, like Asp, Gly, Pro, 
His, and Trp, appeared to be largely avoided in a total of 30 
characterized acyl acceptor (lysine) substrates. We would spec­
ulate that degenerate hexapeptide motifs could also be used in 
vivo. We have shown previously tha t a synthetic peptide com­
prising the NH2-terminal 14 amino acids of processed SKALP/ 
elafin, which contains the degenerate motif GQDTVK, is also 
incorporated efficiently by TGase, suggesting that slight vari­
ations in the surrounding amino acids are tolerated. In the 
same study we used full-length SKALP/elafin purified from 
human keratinocytes and showed that the protein is cross- 
linked to an acyl acceptor probe by the action of type 2 TGase. 
A recent study by Steinert and Mare ko v (21) showed that the 
degenerate AQEPVK and GQDKVK sequences were used for 
cross-linking to loricrin and cytokeratin 1 in vivo, as deter­
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mined by amino acid sequencing of purified peptides from 
human foreskin.
In addition to cross-linking of the GQDPVK hexapeptide to 
its natural substrate proteins in stratum corneum, we also 
used purified control proteins to investigate the substrate spec­
ificity of GQDPVK for these proteins. The biotinylated GQD­
PVK hexapeptide was found to be cross-linked efficiently by 
exogenous type 2 TGase to cd3-crystallin and ß-low-crystallin, 
structural proteins of the vertebrate eye lens (Fig. 5C). These 
proteins are known acyl acceptor substrates for type 2 TGase, 
as the COOH-terminal lysine residue of aB-crystallin was iden­
tified as the site of linkage (30), and a lysine residue in the 
NH2-terminal extension acts as the sole acyl acceptor substrate 
in /3A3-crystallin, which is a component of a /3-low-crystallin 
preparation (31). Two glutamine residues acting as acyl donor 
were characterized in the NH2-termmal region of ßA3-crystal- 
lin by Berbers et al. (54). No cross-linking capacity was found 
using oA-crystallin and y-crystallin as a substrate, which is in 
accordance with experiments described previously by Groenen 
et al. (30, 31). Recombinant SKALP/elafin, which only contains 
the 57 COOH-terminal amino acids of the full-length molecule 
(and thus lacking the TGase substrate domain), and bovine 
serum albumin did not show appreciable cross-linking to GQD­
PVK. To determine the specificity of the GQDPVK hexapeptide 
for cross-linking to stratum corneum proteins by endogenous 
TGase in psoriatic scale extracts, we introduced two other acyl 
donor probes: a biotinylated TVQQEL hexapeptide that is pat­
terned on the NHg-terminal extension of bovine /3A3-crystaIlin 
(30), and a biotinylated PGGQQIV heptapeptide, patterned on 
the amine acceptor sequence in fibronectin (55). Fig. 5D shows 
that the GQDPVK hexapeptide reacts to a greater extent with 
stratum corneum proteins than the other acyl donor probes 
(samples 1-5), whereas they all show the same reactivity to­
ward /3-low-crystallin by the action of exogenous type 2 TGase 
(samples 4-6). This suggests that the GQDPVK motif is a 
preferred substrate for cross-linking to stratum corneum pro­
teins by epidermal TGases*
TGase activity in stratum corneum extracts could be derived 
from TGase types 1> 2, and 3» Previous studies, however, have 
suggested that the bulk of the soluble TGase activity comes 
from TGase type 3 (49). To investigate the relative contribution 
of the various TGase types in stratum corneum extracts we 
used scale extracts from three psoriatic patients (Fig. 5E> sam­
ples I S ) ,  a patient with LI (sarnple 4)> and a patient with 
eczema (sample 5). Surprisingly, the TGase activity measured 
in these five scale extracts was very similar. Assuming that 
TGase 1 would contribute significantly, a decreased TGase 
activity was expected in scale extract from the patient with LI, 
since this patient was homozygous for a splice mutation in 
intron 5 of the TGase type 1 gene as determined by single 
strand conformation polymorphism analysis and sequence 
analysis.2 This mutation causes a deficiency for TGase type 1 
as described recently (24) and is probably the origin for dis­
turbed formation of the cornified envelopes which may explain 
the phenotype of LI. Despite a defect TGase 1 gene in LI, our 
experiments showed that the GQDPVK hexapeptide is still 
cross-linked to stratum corneum proteins by endogenous 
TGases in scale extract from a LI patient. It is most likely that 
TGase type 2 or 3 is responsible for this phenomenon. In a 
recent publication TGases 1, 2 , and 3 were shown to utilize 
loricrin in vitro as a complete substrate, but the types of cross- 
linking were different (56). TGase 1 mostly formed oligomeric 
complexes by interchain cross-links, whereas TGase 3 reactiv-
2 H. Kremer, D. Melchers, A. Pol, P. C. M. van de Kerkhof, and P. M. 
Steijlen, manuscript in preparation.
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F ig. 6. W este rn  b lo t ana lysis  of SDS-PAGE d e m o n s tra t in g  
s t r a tu m  c o rn e u m  p ro te in  c ro ss-link ing  to  a b io t in y la te d  
h ex ap ep tid e . Lanes 1 and 2 , extract of cultured differentiated kerati- 
nocytes stained for protein with Amido Black (lane 1) and processed for 
chemiluminescent detection of cross-linked biotin-GQDPVK {lane 2), 
The majority of the positive hands are found between 30 and 80 kDa. 
Lanes 3 and 4, scale extract from a psoriatic patient stained for protein 
with Amido Black (lane 3) and processed for chemiluminescent detec­
tion of cross-linked biotin-GQDPVK (lane 4). Strong positive bands 
were detected between 30 and 80 kDa, Lanes 5  and 6, Amido Black 
staining of a-crystallin enriched in o-B {lane 5) and processed for chemi­
luminescent detection of cross-linked biotin-GQDPVK to aB-crystallin 
by the action of type 2 TGase (lane 6). As expected, a 22-kDa band is 
positive for incorporation of biotinylated hexapeptide. Lane 7, broad 
range prestained marker,
ity is involved in the formation of intrachain cross-links. The 
participation of TGase 2 in loricrin cross-linking was quite 
weak. It is therefore likely that TGase 3 is the active enzyme in 
the scale extract of the LI patient. Evidence that the GQDPVK 
motif can be used for cross-linking by TGase 1 was obtained by 
using cultured normal epidermal keratinocytes, which do not 
express TGase 3 (49), as a source of TGase type 1 and substrate 
(Fig, 6). Subsequent reaction with the biotinylated GQDPVK 
hexapeptide and analysis by SDS-PAGE show incorporation in 
proteins predominantly between 30 and 80 kDa (Fig. 6 , lane 2). 
For comparison the incorporation pattern in stratum corneum 
proteins from psoriatic epidermis is shown (Fig. 6 , lane 4). 
Cross-linking of GQDPVK to aB-crystallin by TGase 2 is dem­
onstrated in lanes 5 and 6.
To conclude, we have identified novel Trappin family mem­
bers, and we have characterized some of the biochemical prop­
erties of the GQDPVK motif with respect to TGase cross-link­
ing in vitro. In addition to the TGase substrate domain, 
Trappin family members possess a COOH-terminal WAP motif 
that harbors putative proteinase inhibitory activity. The con­
stitutive expression of Trappin gene family members in a num­
ber of normal epithelia which are subjected to continuous me­
chanical and microbial stress or inflammatory stimuli (e.g. oral 
epithelia, esophagus, trachea, ileum) is in line with a role for 
these molecules as proteinase inhibitors with different sub­
strate specificities for self and (possibly) non-self proteases. 
Future research will be directed at investigation of the role of 
other Trappin family members in epithelial homeostasis and 
human diseases.
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